The Experts in Animal Health

Brakke Consulting’s
Animal Health News & Notes for March 17, 2023
Copyright © Brakke Consulting
Editor: Lynn Fondon DVM MBA


Brakke Consulting News
Pain Management Products report – pre-order now

Earnings News
Pet Valu

Other News
Akorn Pharmaceuticals
Parker & Ace
PDX Biotech
Redesign Health
Stratford Care (recall)
Stratford Care (Patterson)
Wild Earth

Pain management is one of the leading topics in veterinary medicine today, and new, innovative products are changing the pain management paradigm. Is your company up-to-date on the latest trends in this important category?

Brakke Consulting’s annual report on Pain Management Products for Dogs and Cats includes such valuable information as:

– estimates of US sales and prices of leading products
– review of new and upcoming pain management products, including ZORBIUM and monoclonal antibody products SOLENSIA and LIBRELA
– discussion of the use of cannabinoids in veterinary pain management
– 2023 survey of 350 small animal veterinarians regarding use of pain management products
– Trended, aggregated practice-level data, powered by Vetsource, including chronic vs. acute use of analgesics, comparisons of analgesic revenue per patient by brand, and data on brand-switching at the patient level.

Pain Management Products for Dogs and Cats 2023 can be purchased for $8,450 if ordered by March 31, 2023, and $8,995 thereafter. The report will be completed in April. Questions about the study can be answered by project manager Lynn Fondon, DVM, MBA at


  • Zomedica reported consolidated financial results for the year ended December 31, 2022. Revenue was $18.9 million, an increase of 361% compared to 2021, primarily driven by a full year of PulseVet sales and the inclusion of the recently acquired Assisi products. When including pre-acquisition sales of PulseVet and Assisi products, Zomedica 2022 revenue was up 25% over 2021 combined revenues. Net loss for the year ended December 31, 2022 was $(17.0) million, compared to a loss of $(18.4) million for the year ended December 31, 2021. (seekingalpha)
  • Pet Valu reported results for the full year 2022. Revenue was C$952 million (US$692 million), a year-over-year increase of 23%. Gross profit increased by C$65.1 million to C$352.3 million (US$256 million). (Globalpets)


  • Zoetis announced the further expansion of Vetscan Imagyst to include two new applications: one for AI dermatology, available now; and another for AI equine FEC analysis, which will be available in Spring 2023. (Thehorse)
  • Vetoquinol announced the launch of VetPowerment, an employee engagement and development tool that allows team members to regularly evaluate each other and the organization. This confidential information is aggregated to help diagnose the organization’s work culture and empower managers to select development training for improvement. (company press release)
  • PDX Biotech announced the launch of OraStripdx, an easy-to-use test strip that can detect active periodontal disease in dogs and cats in 10 seconds. The strip changes color based on the concentration of thiols in the patient’s oral fluid. (DVM360)
  • Swedencare’s subsidiary Stratford Care USA, announced that it has executed a long-term agreement with Patterson Veterinary, wherein Patterson acquired the exclusive rights to market and promote the animal pharmaceuticals brand of dermatology, dental and nutritional products for the US veterinary market. (Marketscreener)
  • Akorn Pharmaceuticals announced it has filed for chapter 7 bankruptcy and is shutting down US operations. (Fierce Pharma)
  • Stratford Care USA, Inc. announced it is recalling multiple brands of omega-3 supplements for cats and dogs due to potentially elevated levels of Vitamin A. Stratford Care USA is taking this action after receiving a single serious adverse event from a sole consumer regarding their dogs’ exhibiting signs of Vitamin A toxicity after consuming the supplement. (FDA)
  • Wild Earth announced the launch of its new plant-based dog foods: Wild Earth Performance Formula, which has 28% fungi and plant-based proteins; and Wild Earth Core Formula with 23% fungi and plant-based proteins. Both lines are formulated without beef, dairy, chicken, wheat, or lamb. (Pet Business)
  • Redesign Health announced that Parker & Ace is opening its first veterinary clinic location in Washington, D.C. Parker & Ace is establishing full-service, membership-based clinics; for a one-year price of $159 per pet, founding members get same-day and next-day appointments, complimentary exams, and 24/7 telehealth services. (Todays Veterinary Business)



  • SWITZERLAND – BSE Switzerland reported a case of bovine spongiform encephalopathy (BSE) in the eastern region of Grisons. The 12-year-old cow was sampled on Feb. 27 at slaughter as part of the BSE surveillance program; the case was classified as atypical. (Reuters)

Last week, Paul Casady and I attended the Animal Health, Nutrition & Technology Innovation Europe conference held in London.  We conducted two sold-out round table sessions on the topic, “From Startup to Grownup, Go To Market Strategies for Companies in the Animal Health Industry – and why It’s All About People”.  The Kisaco Research team produced the well-attended event, showcased 19 startup companies, and brought in some energetic speakers.

One of those speakers was Sven Smit, Chair of the McKinsey Global Institute (MGI), and he made everyone listening start to think about what’s next for the global economy.  He thinks the world is not just going through another business cycle, but is on the cusp of a new era, which is driven by the global pandemic, energy scarcity, rapid inflation and geopolitical tensions.  The data presented was taken from a new paper from the MGI and he highlighted three past eras: the Postwar Boom (1944–71), the Era of Contention (1971–89), and the Era of Markets (1989–2019).

The most remarkable part of his presentation was on energy systems and how utterly unprepared we are as a global economy to achieve net-zero and how utterly dependent the global economy, including animal, feed and food production, is on fossil fuels.  Mr. Smit wouldn’t speculate on a name for the new era and I won’t either, although if I did, it would have something to do with energy supply.

Bob Jones

Last week, we asked you about innovation in the livestock segment and two thirds of our respondents thought investment should be in the preventative area, vaccines, non-antibiotic products, parasiticides, etc.  The remaining third was evenly split between therapeutic products, like antibiotics, and technology products, like animal ID and traceability products.

This Week:
This week, let’s test your energy knowledge and no peeking at the paper linked in the Viewpoint above.  According to the International Energy Agency, between the year 2000 and 2014, the investment in energy supply infrastructure around the world grew 7.7% per year, reaching just over $2 trillion.

 From 2014 to 2022, what has growth in energy supply infrastructure investment been?


en_USEnglish (United States)